IL17A and Obesity: In particular, the anti-IL-17 group exhibited a higher prevalence of obesity and significantly elevated TMAO levels compared to the anti-IL-23 group (6.84 ± 6.51 vs. 2.88 ± 2.52, p = 0.03).